Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 361

1.

Systematic Review and Meta-Analysis: Is There a Benefit in Using Neoadjuvant Systemic Chemotherapy in Locally Advanced Penile Squamous Cell Carcinoma?

Azizi M, Aydin AM, Hajiran A, Lai A, Kumar A, Peyton CC, Minhas S, Sonpavde GP, Chahoud J, Pagliaro LC, Necchi A, Spiess PE.

J Urol. 2020 Jan 13:101097JU0000000000000746. doi: 10.1097/JU.0000000000000746. [Epub ahead of print]

PMID:
31928407
2.

Renal toxicity with mammalian target of rapamycin inhibitors: A meta-analysis of randomized clinical trials.

Paluri RK, Sonpavde G, Morgan C, Rojymon J, Mar AH, Gangaraju R.

Oncol Rev. 2019 Nov 25;13(2):455. doi: 10.4081/oncol.2019.455. eCollection 2019 Jul 22.

3.

A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma.

Nassar AH, Mouw KW, Jegede O, Shinagare AB, Kim J, Liu CJ, Pomerantz M, Harshman LC, Van Allen EM, Wei XX, McGregor B, Choudhury AD, Preston MA, Dong F, Signoretti S, Lindeman NI, Bellmunt J, Choueiri TK, Sonpavde G, Kwiatkowski DJ.

Br J Cancer. 2019 Dec 20. doi: 10.1038/s41416-019-0686-0. [Epub ahead of print]

PMID:
31857723
4.

Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma.

Nassar AH, Abou Alaiwi S, AlDubayan SH, Moore N, Mouw KW, Kwiatkowski DJ, Choueiri TK, Curran C, Berchuck JE, Harshman LC, Nuzzo PV, Chanza NM, Van Allen E, Esplin ED, Yang S, Callis T, Garber JE, Rana HQ, Sonpavde G.

Genet Med. 2019 Dec 17. doi: 10.1038/s41436-019-0720-x. [Epub ahead of print]

PMID:
31844177
5.

Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with checkpoint inhibitors.

Khaki AR, Li A, Diamantopoulos LN, Bilen MA, Santos V, Esther J, Morales-Barrera R, Devitt M, Nelson A, Hoimes CJ, Shreck E, Assi H, Gartrell BA, Sankin A, Rodriguez-Vida A, Lythgoe M, Pinato DJ, Drakaki A, Joshi M, Isaacsson Velho P, Hahn N, Liu S, Alonso Buznego L, Duran I, Moses M, Jain J, Murgic J, Baratam P, Barata P, Tripathi A, Zakharia Y, Galsky MD, Sonpavde G, Yu EY, Shankaran V, Lyman GH, Grivas P.

Cancer. 2019 Dec 12. doi: 10.1002/cncr.32645. [Epub ahead of print]

PMID:
31829450
6.

ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer.

Sonpavde G, Necchi A, Gupta S, Steinberg GD, Gschwend JE, Van Der Heijden MS, Garzon N, Ibrahim M, Raybold B, Liaw D, Rutstein M, Galsky MD.

Future Oncol. 2020 Jan;16(2):4359-4368. doi: 10.2217/fon-2019-0611. Epub 2019 Dec 11.

7.

Comprehensive Analysis of AR Alterations in Circulating Tumor DNA from Patients with Advanced Prostate Cancer.

Ledet EM, Lilly MB, Sonpavde G, Lin E, Nussenzveig RH, Barata PC, Yandell M, Nagy RJ, Kiedrowski L, Agarwal N, Sartor O.

Oncologist. 2019 Nov 11. pii: theoncologist.2019-0115. doi: 10.1634/theoncologist.2019-0115. [Epub ahead of print]

8.

Correction to: Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma.

Ghatalia P, Gordetsky J, Kuo F, Dulaimi E, Cai KQ, Devarajan K, Bae S, Naik G, Chan TA, Uzzo R, Hakimi AA, Sonpavde G, Plimack E.

J Immunother Cancer. 2019 Oct 22;7(1):273. doi: 10.1186/s40425-019-0735-5.

9.

Erdafitinib in Urothelial Carcinoma.

Sonpavde G, Sjödahl G.

N Engl J Med. 2019 Oct 17;381(16):1594. doi: 10.1056/NEJMc1911187. No abstract available.

PMID:
31618552
10.

Trends in Adherence to Thromboprophylaxis Guideline in Patients Undergoing Radical Cystectomy.

Tully KH, Krimphove MJ, Reese SW, Kibel AS, Noldus J, Krasnow RE, Trinh QD, Sonpavde GP, Chang SL, Mossanen M.

Urology. 2020 Jan;135:44-49. doi: 10.1016/j.urology.2019.09.029. Epub 2019 Oct 3.

PMID:
31586570
11.

Investigational MET inhibitors to treat Renal cell carcinoma.

Nandagopal L, Sonpavde GP, Agarwal N.

Expert Opin Investig Drugs. 2019 Oct;28(10):851-860. doi: 10.1080/13543784.2019.1673366. Epub 2019 Oct 3. Review.

PMID:
31554440
12.

Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma.

McGregor BA, Sonpavde G.

Expert Opin Investig Drugs. 2019 Oct;28(10):821-826. doi: 10.1080/13543784.2019.1667332. Epub 2019 Sep 17. Review.

PMID:
31526130
13.

Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study.

Grivas P, Lalani AA, Pond GR, Nagy RJ, Faltas B, Agarwal N, Gupta SV, Drakaki A, Vaishampayan UN, Wang J, Barata PC, Gopalakrishnan D, Naik G, McGregor BA, Kiedrowski LA, Lanman RB, Sonpavde GP.

Eur Urol Oncol. 2019 Mar 9. pii: S2588-9311(19)30028-8. doi: 10.1016/j.euo.2019.02.004. [Epub ahead of print]

PMID:
31412004
14.

Predictive Role of Computed Tomography Texture Analysis in Patients with Metastatic Urothelial Cancer Treated with Programmed Death-1 and Programmed Death-ligand 1 Inhibitors.

Alessandrino F, Gujrathi R, Nassar AH, Alzaghal A, Ravi A, McGregor B, Sonpavde G, Shinagare AB.

Eur Urol Oncol. 2019 Mar 9. pii: S2588-9311(19)30026-4. doi: 10.1016/j.euo.2019.02.002. [Epub ahead of print]

PMID:
31412003
15.

Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials.

Sonpavde GP, Pond GR, Fizazi K, de Bono JS, Basch EM, Scher HI, Smith MR.

Eur Urol Oncol. 2018 Nov 30. pii: S2588-9311(18)30204-9. doi: 10.1016/j.euo.2018.11.006. [Epub ahead of print]

PMID:
31412002
16.

Expression and Role of Methylenetetrahydrofolate Dehydrogenase 1 Like (MTHFD1L) in Bladder Cancer.

Eich ML, Rodriguez Pena MDC, Chandrashekar DS, Chaux A, Agarwal S, Gordetsky JB, Ferguson JE, Sonpavde GP, Netto GJ, Varambally S.

Transl Oncol. 2019 Nov;12(11):1416-1424. doi: 10.1016/j.tranon.2019.07.012. Epub 2019 Aug 8.

17.

A new subtyping model for residual invasive disease after cisplatin-based neoadjuvant chemotherapy for muscle invasive bladder cancer.

Agarwal A, Sonpavde G.

Transl Androl Urol. 2019 Jul;8(Suppl 3):S254-S256. doi: 10.21037/tau.2018.12.10. No abstract available.

18.

Advanced urothelial cancer: a radiology update.

Alessandrino F, Ghaith O, Williams K, Sonpavde GP, Silverman SG, Shinagare AB.

Abdom Radiol (NY). 2019 Dec;44(12):3858-3873. doi: 10.1007/s00261-019-02148-3. Review.

PMID:
31363813
19.

Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma.

Ghatalia P, Gordetsky J, Kuo F, Dulaimi E, Cai KQ, Devarajan K, Bae S, Naik G, Chan TA, Uzzo R, Hakimi AA, Sonpavde G, Plimack E.

J Immunother Cancer. 2019 May 28;7(1):139. doi: 10.1186/s40425-019-0621-1. Erratum in: J Immunother Cancer. 2019 Oct 22;7(1):273.

20.

Role of Checkpoint Inhibition in Localized Bladder Cancer.

Hahn NM, Necchi A, Loriot Y, Powles T, Plimack ER, Sonpavde G, Roupret M, Kamat AM.

Eur Urol Oncol. 2018 Aug;1(3):190-198. doi: 10.1016/j.euo.2018.05.002. Epub 2018 May 30.

PMID:
31102620
21.

Conceptual Framework for Therapeutic Development Beyond Anti-PD-1/PD-L1 in Urothelial Cancer.

Grivas P, Drakaki A, Friedlander TW, Sonpavde G.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:284-300. doi: 10.1200/EDBK_237449. Epub 2019 May 17. Review.

22.

Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor.

Ferro M, Di Lorenzo G, Vartolomei MD, Bruzzese D, Cantiello F, Lucarelli G, Musi G, Di Stasi S, Hurle R, Guazzoni G, Busetto GM, Gabriele A, Del Giudice F, Damiano R, Perri F, Perdona S, Verze P, Borghesi M, Schiavina R, Almeida GL, Bove P, Lima E, Autorino R, Crisan N, Farhan ARA, Battaglia M, Russo GI, Ieluzzi V, Morgia G, De Placido P, Terracciano D, Cimmino A, Scafuri L, Mirone V, De Cobelli O, Shariat S, Sonpavde G, Buonerba C.

World J Urol. 2020 Jan;38(1):143-150. doi: 10.1007/s00345-019-02754-2. Epub 2019 Apr 16.

PMID:
30993426
23.

Prostate cancer cells hyper-activate CXCR6 signaling by cleaving CXCL16 to overcome effect of docetaxel.

Kapur N, Mir H, Sonpavde GP, Jain S, Bae S, Lillard JW Jr, Singh S.

Cancer Lett. 2019 Jul 10;454:1-13. doi: 10.1016/j.canlet.2019.04.001. Epub 2019 Apr 8.

PMID:
30974114
24.

Rare Genitourinary Malignancies: Current Status and Future Directions of Immunotherapy.

McGregor BA, Sonpavde GP.

Eur Urol Focus. 2020 Jan 15;6(1):14-16. doi: 10.1016/j.euf.2019.03.011. Epub 2019 Mar 23. Review.

PMID:
30910391
25.

Use of Quantitative T2-Weighted and Apparent Diffusion Coefficient Texture Features of Bladder Cancer and Extravesical Fat for Local Tumor Staging After Transurethral Resection.

Lim CS, Tirumani S, van der Pol CB, Alessandrino F, Sonpavde GP, Silverman SG, Shinagare AB.

AJR Am J Roentgenol. 2019 Mar 12:1-10. doi: 10.2214/AJR.18.20718. [Epub ahead of print]

PMID:
30860885
26.

Mitochondrial localization, import, and mitochondrial function of the androgen receptor.

Bajpai P, Koc E, Sonpavde G, Singh R, Singh KK.

J Biol Chem. 2019 Apr 19;294(16):6621-6634. doi: 10.1074/jbc.RA118.006727. Epub 2019 Feb 21.

PMID:
30792308
27.

Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer.

Einstein DJ, Sonpavde G.

Curr Treat Options Oncol. 2019 Feb 11;20(2):12. doi: 10.1007/s11864-019-0609-6. Review.

PMID:
30741358
28.

Loss of FOXP3 and TSC1 Accelerates Prostate Cancer Progression through Synergistic Transcriptional and Posttranslational Regulation of c-MYC.

Wu L, Yi B, Wei S, Rao D, He Y, Naik G, Bae S, Liu XM, Yang WH, Sonpavde G, Liu R, Wang L.

Cancer Res. 2019 Apr 1;79(7):1413-1425. doi: 10.1158/0008-5472.CAN-18-2049. Epub 2019 Feb 7.

PMID:
30733194
29.

Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival?

Cole AP, Fletcher SA, Berg S, Nabi J, Mahal BA, Sonpavde GP, Nguyen PL, Lipsitz SR, Sun M, Choueiri TK, Preston MA, Kibel AS, Trinh QD.

Cancer. 2019 Apr 15;125(8):1319-1329. doi: 10.1002/cncr.31926. Epub 2019 Jan 11.

PMID:
30633323
30.

Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.

Sonpavde G, Agarwal N, Pond GR, Nagy RJ, Nussenzveig RH, Hahn AW, Sartor O, Gourdin TS, Nandagopal L, Ledet EM, Naik G, Armstrong AJ, Wang J, Bilen MA, Gupta S, Grivas P, Pal SK, Lanman RB, Talasaz A, Lilly MB.

Cancer. 2019 May 1;125(9):1459-1469. doi: 10.1002/cncr.31959. Epub 2019 Jan 8.

PMID:
30620391
31.

Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter?

Berg S, D'Andrea D, Vetterlein MW, Cole AP, Fletcher SA, Krimphove MJ, Marchese M, Lipsitz SR, Sonpavde G, Noldus J, Shariat SF, Kibel AS, Trinh QD, Mossanen M.

Cancer. 2019 May 1;125(9):1449-1458. doi: 10.1002/cncr.31952. Epub 2019 Jan 8.

PMID:
30620387
32.

Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites.

Nassar AH, Umeton R, Kim J, Lundgren K, Harshman L, Van Allen EM, Preston M, Dong F, Bellmunt J, Mouw KW, Choueiri TK, Sonpavde G, Kwiatkowski DJ.

Clin Cancer Res. 2019 Apr 15;25(8):2458-2470. doi: 10.1158/1078-0432.CCR-18-3147. Epub 2018 Dec 28.

PMID:
30593515
33.

Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes.

Grivas P, Mortazavi A, Picus J, Hahn NM, Milowsky MI, Hart LL, Alva A, Bellmunt J, Pal SK, Bambury RM, O'Donnell PH, Gupta S, Guancial EA, Sonpavde GP, Faltaos D, Potvin D, Christensen JG, Chao RC, Rosenberg JE.

Cancer. 2019 Feb 15;125(4):533-540. doi: 10.1002/cncr.31817. Epub 2018 Dec 20.

34.

Examining the relationship between complications and perioperative mortality following radical cystectomy: a population-based analysis.

Mossanen M, Krasnow RE, Zlatev DV, Tan WS, Preston MA, Trinh QD, Kibel AS, Sonpavde G, Schrag D, Chung BI, Chang SL.

BJU Int. 2019 Jul;124(1):40-46. doi: 10.1111/bju.14636. Epub 2019 Apr 14.

PMID:
30499636
35.

Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories.

Mossanen M, Wang Y, Szymaniak J, Tan WS, Huynh MJ, Preston MA, Trinh QD, Sonpavde G, Kibel AS, Chang SL.

World J Urol. 2019 Oct;37(10):2059-2065. doi: 10.1007/s00345-018-2550-x. Epub 2018 Nov 16.

PMID:
30446799
36.

Systemic treatments for metastatic urothelial carcinoma.

Lalani AA, Sonpavde GP.

Expert Opin Pharmacother. 2019 Feb;20(2):201-208. doi: 10.1080/14656566.2018.1544242. Epub 2018 Nov 9. Review.

PMID:
30412003
37.

Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing.

Slavin TP, Banks KC, Chudova D, Oxnard GR, Odegaard JI, Nagy RJ, Tsang KWK, Neuhausen SL, Gray SW, Cristofanilli M, Rodriguez AA, Bardia A, Leyland-Jones B, Janicek MF, Lilly M, Sonpavde G, Lee CE, Lanman RB, Meric-Bernstam F, Kurzrock R, Weitzel JN.

J Clin Oncol. 2018 Oct 19:JCO1800328. doi: 10.1200/JCO.18.00328. [Epub ahead of print]

38.

SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer.

Merseburger AS, Apolo AB, Chowdhury S, Hahn NM, Galsky MD, Milowsky MI, Petrylak D, Powles T, Quinn DI, Rosenberg JE, Siefker-Radtke A, Sonpavde G, Sternberg CN.

World J Urol. 2019 Jan;37(1):95-105. doi: 10.1007/s00345-018-2486-1. Epub 2018 Sep 20. Review.

PMID:
30238401
39.

Treating Patients With Bladder Cancer: Is There an Ethical Obligation to Include Smoking Cessation Counseling?

Mossanen M, Caldwell J, Sonpavde G, Lehmann LS.

J Clin Oncol. 2018 Sep 13:JCO1800577. doi: 10.1200/JCO.18.00577. [Epub ahead of print] No abstract available.

PMID:
30212292
40.

Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer.

Armstrong AJ, Lin P, Higano CS, Sternberg CN, Sonpavde G, Tombal B, Templeton AJ, Fizazi K, Phung D, Wong EK, Krivoshik A, Beer TM.

Ann Oncol. 2018 Nov 1;29(11):2200-2207. doi: 10.1093/annonc/mdy406.

41.

An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma.

Choueiri TK, Michaelson MD, Posadas EM, Sonpavde GP, McDermott DF, Nixon AB, Liu Y, Yuan Z, Seon BK, Walsh M, Jivani MA, Adams BJ, Theuer CP.

Oncologist. 2019 Feb;24(2):202-210. doi: 10.1634/theoncologist.2018-0299. Epub 2018 Sep 6.

42.

Immunotherapy for advanced penile cancer - rationale and potential.

McGregor B, Sonpavde G.

Nat Rev Urol. 2018 Dec;15(12):721-723. doi: 10.1038/s41585-018-0083-0. No abstract available.

PMID:
30166593
43.

Integrative Epigenetic and Gene Expression Analysis of Renal Tumor Progression to Metastasis.

Nam HY, Chandrashekar DS, Kundu A, Shelar S, Kho EY, Sonpavde G, Naik G, Ghatalia P, Livi CB, Varambally S, Sudarshan S.

Mol Cancer Res. 2019 Jan;17(1):84-96. doi: 10.1158/1541-7786.MCR-17-0636. Epub 2018 Aug 21.

44.

A Role for De Novo Purine Metabolic Enzyme PAICS in Bladder Cancer Progression.

Chakravarthi BVSK, Rodriguez Pena MDC, Agarwal S, Chandrashekar DS, Hodigere Balasubramanya SA, Jabboure FJ, Matoso A, Bivalacqua TJ, Rezaei K, Chaux A, Grizzle WE, Sonpavde G, Gordetsky J, Netto GJ, Varambally S.

Neoplasia. 2018 Sep;20(9):894-904. doi: 10.1016/j.neo.2018.07.006. Epub 2018 Aug 15.

45.

Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma.

Sonpavde GP, Mariani L, Lo Vullo S, Raggi D, Giannatempo P, Bamias A, Crabb SJ, Bellmunt J, Yu EY, Niegisch G, Vaishampayan UN, Theodore C, Berthold DR, Srinivas S, Sridhar SS, Plimack ER, Rosenberg JE, Powles T, Galsky MD, Necchi A.

J Urol. 2018 Dec;200(6):1207-1214. doi: 10.1016/j.juro.2018.07.035. Epub 2018 Sep 4.

46.

Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era.

Fletcher SA, Harmouch SS, Krimphove MJ, Cole AP, Berg S, Gild P, Preston MA, Sonpavde GP, Kibel AS, Sun M, Choueiri TK, Trinh QD.

World J Urol. 2018 Nov;36(11):1767-1774. doi: 10.1007/s00345-018-2371-y. Epub 2018 Jun 14.

PMID:
29948050
47.

Can RECIST response predict success in phase 3 trials in men with metastatic castration-resistant prostate cancer?

Brown LC, Sonpavde G, Armstrong AJ.

Prostate Cancer Prostatic Dis. 2018 Sep;21(3):419-430. doi: 10.1038/s41391-018-0049-6. Epub 2018 Jun 1.

PMID:
29858595
48.

Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2).

Rosenberg JE, Hahn NM, Regan MM, Werner L, Alva A, George S, Picus J, Alter R, Balar A, Hoffman-Censits J, Grivas P, Lauer R, Guancial EA, Hoimes C, Sonpavde G, Albany C, Stein MN, Breen T, Jacobs C, Anderson K, Bellmunt J, Lalani AA, Pal S, Choueiri TK.

Br J Cancer. 2018 May;118(11):1434-1441. doi: 10.1038/s41416-018-0087-9. Epub 2018 May 16.

49.

Real-World Effectiveness of Chemotherapy in Elderly Patients With Metastatic Bladder Cancer in the United States.

Galsky MD, Pal SK, Lin SW, Ogale S, Zivkovic M, Simpson J, Derleth C, Schiff C, Sonpavde G.

Bladder Cancer. 2018 Apr 26;4(2):227-238. doi: 10.3233/BLC-170149.

50.

Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study.

Gordon JA, Buonerba C, Pond G, Crona D, Gillessen S, Lucarelli G, Rossetti S, Dorff T, Artale S, Locke JA, Bosso D, Milowsky MI, Witek MS, Battaglia M, Pignata S, Cherhroudi C, Cox ME, De Placido P, Ribera D, Omlin A, Buonocore G, Chi K, Kollmannsberger C, Khalaf D, Facchini G, Sonpavde G, De Placido S, Eigl BJ, Di Lorenzo G.

Oncotarget. 2018 Apr 13;9(28):19861-19873. doi: 10.18632/oncotarget.24888. eCollection 2018 Apr 13.

Supplemental Content

Loading ...
Support Center